ContraVir Pharmaceuticals, Inc. Contracts & Agreements
67 Contracts & Agreements
- Business Finance (45 contracts)
- Business Operations (5)
- Human Resources (1)
- Intellectual Property (1)
- Mergers & Acquisitions (3)
- Uncategorized (12)
- Form of Lock-Up Agreement by and between the Company and each of the parties named in each agreement thereof (Filed With SEC on July 22, 2024)
- Agreement and Plan of Merger, dated as of July 19, 2024, by and among the Company, Parent and Merger Sub (Filed With SEC on July 22, 2024)
- Form of Senior Unsecured Nonconvertible Note (Filed With SEC on July 22, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on July 22, 2024)
- Form of Registration Rights Agreement (Filed With SEC on July 22, 2024)
- Form of Company Support Agreement by and between the Company and each of the parties named in each agreement thereof (Filed With SEC on July 22, 2024)
- Form of Series B-1 Warrant (Filed With SEC on February 16, 2024)
- Form of Series B-2 Warrant (Filed With SEC on February 16, 2024)
- Form of Warrant Inducement Agreement (Filed With SEC on February 16, 2024)
- Form of Amendment No. 1 to Series ACommon Stock Purchase Warrant (Filed With SEC on February 16, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on October 3, 2023)
- Form of Series A Warrant (Filed With SEC on October 3, 2023)
- Form of Series B Warrant (Filed With SEC on October 3, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on October 3, 2023)
- Controlled Equity Offering Sales Agreement dated July 21, 2023 by and between Hepion Pharmaceuticals, Inc., and Cantor Fitzgerald & Co (Filed With SEC on July 21, 2023)
- Form of Securities Purchase Agreement between Hepion Pharmaceuticals, Inc. and the investors thereto, dated November 4, 2022 (Filed With SEC on November 9, 2022)
- Form of Registration Rights Agreement between Hepion Pharmaceuticals, Inc. and the investors thereto, dated November 4, 2022 (Filed With SEC on November 9, 2022)
- Form of Side Letter between Hepion Pharmaceuticals, Inc. and each investor, dated November 4, 2022 (Filed With SEC on November 9, 2022)
- Underwriting Agreement, dated February 16, 2021 (Filed With SEC on February 17, 2021)
- Underwriting Agreement, dated November 24, 2020 (Filed With SEC on November 27, 2020)
- Form of Pre-Funded Warrant (Filed With SEC on November 20, 2020)
- Form of Representatives Warrant (Filed With SEC on November 20, 2020)
- Form of Underwriting Agreement (Filed With SEC on November 20, 2020)
- Amendment No. 1 to NICAMS Purchase and Sale Agreement by and between Aurinia Pharmaceuticals Inc., Ciclofilin Pharmaceuticals Inc., an Alberta Corporation and Ciclofilin... (Filed With SEC on November 12, 2020)
- NICAMS Purchase and Sale Agreement by and between Ciclofilin Pharmaceuticals Corp. and Aurinia Pharmaceuticals, Inc. dated February 14, 2014 (Filed With SEC on November 12, 2020)
- Form of Common Stock Purchase Warrant dated June 14, 2018 (Filed With SEC on November 12, 2020)
- Agreement and Plan of Merger by and among the Company, Ciclofilin Acquisition Corp., Ciclofilin Pharmaceuticals, Inc. and Robert Foster, Pharm.D., PH.D., as Stockholder... (Filed With SEC on October 29, 2020)
- Promissory Note dated April 13, 2020 (Filed With SEC on October 29, 2020)
- Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on May 14, 2020)
- At Market Issuance Sales Agreement, dated February 12, 2020, by and between Hepion Pharmaceuticals, Inc. and B. Riley FBR, Inc (Filed With SEC on February 12, 2020)
- Form of Securities Purchase Agreement (Filed With SEC on June 5, 2019)
- Form of Warrant (Filed With SEC on June 5, 2019)
- Form of Co-Placement Agency Agreement (Filed With SEC on June 5, 2019)
- Form of Securities Purchase Agreement (Filed With SEC on April 18, 2019)
- Form of Warrant (Filed With SEC on April 18, 2019)
- Form of Placement Agency Agreement (Filed With SEC on April 18, 2019)
- Form of Unsecured Debenture issued to Investor, dated March 14, 2019 (Filed With SEC on March 19, 2019)
- Form of Securities Purchase Agreement, dated March 13, 2019, by and among the Company and the Investor (Filed With SEC on March 19, 2019)
- Settlement Agreement and General Release between ContraVir Pharmaceuticals, Inc. and Theresa Matkovits dated as of October 15, 2018 (Filed With SEC on November 14, 2018)
- Separation Agreement and General Release between ContraVir Pharmaceuticals, Inc. and James Sapirstein dated as of October 18, 2018 (Filed With SEC on November 14, 2018)
- Warrant Agency Agreement, dated as of July 2, 2018, by and between the Company and Philadelphia Stock Transfer, Inc (Filed With SEC on July 5, 2018)
- Form of Dealer-Manager Agreement (Filed With SEC on June 13, 2018)
- Form of Dealer-Manager Agreement (Filed With SEC on June 4, 2018)
- Form of Non-Transferable Subscription Rights Certificate (Filed With SEC on June 4, 2018)
- Form of Warrant Agreement (Filed With SEC on June 4, 2018)
- Form of Warrant Certificate (Filed With SEC on June 4, 2018)
- Secured Convertible Promissory Note, dated May 8, 2018, by and between ContraVir Pharmaceuticals, Inc. and Iliad Research and Trading, L.P (Filed With SEC on May 15, 2018)
- Securities Purchase Agreement, dated May 8, 2018, by and between ContraVir Pharmaceuticals, Inc. and Iliad Research and Trading, L.P (Filed With SEC on May 15, 2018)
- Security Agreement, dated May 8, 2018, by and between ContraVir Pharmaceuticals, Inc. and Iliad Research and Trading, L.P (Filed With SEC on May 15, 2018)
- AMENDED AND RESTATED EXECUTIVE AGREEMENT (Filed With SEC on May 26, 2017)
- CONTRAVIR PHARMACEUTICALS, INC. (a Delaware corporation) 12,000,000 Shares of Common Stock Warrants to Purchase 6,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 25, 2017)
- [FORM OF WARRANT] (Filed With SEC on April 25, 2017)
- EXECUTIVE AGREEMENT (Filed With SEC on June 13, 2016)
- AGREEMENT AND PLAN OF MERGER BY AND AMONG CONTRAVIR PHARMACEUTICALS, INC., CICLOFILIN ACQUISITION CORP., CICLOFILIN PHARMACEUTICALS, INC. AND ROBERT FOSTER, PHARM.D., PH.D., AS... (Filed With SEC on May 31, 2016)
- EXECUTIVE AGREEMENT (Filed With SEC on March 31, 2016)
- CONTRAVIR PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on March 30, 2016)
- CONTRAVIR PHARMACEUTICALS, INC. 4,929,578 Shares of Common Stock and Warrants to Purchase 2,484,789 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 30, 2016)
- CONTRAVIR PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on October 7, 2015)
- CONTRAVIR PHARMACEUTICALS, INC. 5,000,000 Shares of Common Stock and Warrants to Purchase 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on October 7, 2015)
- LICENSE AGREEMENT (Filed With SEC on February 12, 2015)
- EXECUTIVE AGREEMENT (Filed With SEC on January 15, 2015)
- STOCK PURCHASE AGREEMENT (Filed With SEC on October 15, 2014)
- EXECUTIVE AGREEMENT (Filed With SEC on June 26, 2014)
- EXECUTIVE AGREEMENT (Filed With SEC on March 20, 2014)
- SUBSCRIPTION BOOKLET CONTRAVIR PHARMACEUTICALS, INC. UNITS CONSISTING OF COMMON STOCK AND WARRANTS JANUARY 17, 2014 (Filed With SEC on February 5, 2014)
- COMMON STOCK PURCHASE WARRANT CONTRAVIR PHARMACEUTICALS, INC. (Filed With SEC on February 5, 2014)
- AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (Filed With SEC on November 19, 2013)
